Novo Nordisk to focus on patient outreach, prescribing doctors and subsidies to reach obesity goals

Today, around 125,000 severely obese patients in the US are being treated with one of Novo Nordisk’s obesity drugs. Still, the real demand is yet unclear to the Danish pharmaceutical firm.

Photo: Novo Nordisk / PR

Obese patients can feel confused and stigmatized, and reaching out to men in particular can be difficult. On top of this, Danish pharmaceutical firm Novo Nordisk has recently been hit by big production issues.

There are plenty of challenges on the road to attaining the dream of treating obesity, first in the US and later in the rest of the world. Still, the rewards could be even greater, offering the opportunity to catapult Novo Nordisk into uncharted territory.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs